Centessa has been formed as a biotech conglomerate with $250m in funding following a ten-way merger, including multiple spinouts.
US-based pharmaceutical conglomerate Centessa Pharmaceuticals has been formed by investment firm Medicxi and equipped with $250m in series A financing following a large-scale merger that involved a host of spinouts.
Three spinouts of University of Cambridge – haemophilia treatment developer Apcintex, pulmonary arterial hypertension therapy developer Morphogen-IX and liver and lung diseases drug producer Z-Factor – have been absorbed into Centessa.
The ten-way merger also involved University of Toronto Mississauga’s biopharmaceutical spinout Janpix, kidney…
